

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Bod Science Limited (Subject to a Deed of Company Arrangement)

ABN

89 601 225 441

Quarter ended ("current quarter")

30 September 2025

Consolidated statement of cash flows	Current quarter	Year to date (3 months)
	\$A'000	\$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers ¹	540	540
1.2 Payments for		
(a) research and development	-	-
(b) product manufacturing and operating costs ¹	(185)	(185)
(c) advertising and marketing	(5)	(5)
(d) leased assets	-	-
(e) staff costs	(176)	(176)
(f) administration and corporate costs ²	(1,251)	(1,251)
1.3 Dividends received	-	-
1.4 Interest received	5	5
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other ³	496	496
1.9 Net cash from / (used in) operating activities	(576)	(576)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-
(e) intellectual property	-	-

For personal use only

Consolidated statement of cash flows		Current quarter	Year to date (3 months)
		\$A'000	\$A'000
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received	-	-
2.5	Other	-	-
2.6	Net cash from / (used in) investing activities	-	-

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	-	-

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period ⁴	637	637
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(576)	(576)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-

Consolidated statement of cash flows		Current quarter	Year to date (3 months)
		\$A'000	\$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	-
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of period⁴	61	61

5.	Reconciliation of cash and cash equivalents	Current quarter	Previous quarter
	at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	\$A'000	\$A'000
5.1	Bank balances	522	1,498
5.2	Call deposits	-	-
5.3	Bank overdrafts	(461)	(461)
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	61	1,037

6.	Payments to related parties of the entity and their associates	Current quarter
		\$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1: <ul style="list-style-type: none"> • Salaries/fees paid to directors 	35
6.2	Aggregate amount of payments to related parties and their associates included in item 1	35

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

For personal use only

7. Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities	-	-
7.5 Unused financing facilities available at quarter end		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (item 1.9)	(576)
8.2 Cash and cash equivalents at quarter end (item 4.6)	61
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	61
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	0.11
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
No. The operating cash outflow for the current quarter included an amount of \$1,059k representing the payment of administration and other fees incurred since the start of the administration period. Without these payments, the Company would have generated a positive net cash inflow from operating activities.	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
The Company is operating under a DOCA and its operations are being funded by Biortica under that DOCA in order for a backdoor listing by Biortica to proceed.	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Yes. The Company is operating under a DOCA and its operations are being funded by Biortica under that DOCA in order for a backdoor listing by Biortica to proceed.	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 15 October 2025

Authorised by: **Deed Administrator of Bod Science Limited (Subject to a Deed of Company Arrangement)**

Notes

1. The September 2025 quarter receipts from customers and payments for product manufacturing and operating costs have both been increased by \$151k, representing the grossing up of these line items for payments made by Bod distributors directly to a Bod supplier in relation to the supply of products to Bod by that supplier which were subsequently sold to that distributor.
2. Payments for administration and corporate costs during the September 2025 quarter include administration fees of \$584k and legal and other fees of \$475k incurred since the start of the administration.
3. During the September 2025 quarter, and in accordance with the conditions of the Heads of Agreement between Bod and Biortica Agrimed Limited (Biortica) signed on 9 February 2024, Biortica has partially funded the ongoing trading costs of the company. The funding from Biortica has been disclosed as other inflows from operating activities, while the costs have been disclosed as outflows on the relevant lines within operating activities.
4. During the year ended 30 June 2025, Bod received an R&D tax incentive relating to R&D spend incurred during the year ended 30 June 2024. An amount of \$400k of this R&D tax incentive is held in trust for the benefit of Biortica if the acquisition of Bod completes and this amount has been classified in the Statement of Financial Position as Other assets rather than as Cash and cash equivalents. The opening balance of Cash and cash equivalents has been adjusted accordingly.